

**The Belgian Competition Authority is conducting inspections in the pharmaceutical sector**

The Investigation and Prosecution Service of the Belgian Competition Authority (BCA) is currently conducting inspections at the premises of companies suspected of having implemented restrictive practices aimed at limiting, delaying or even preventing the entry into the market or the expansion of biosimilar medicines competing with existing medicines. These practices could constitute possible infringements of Article IV.1 and/or IV.2 of the Code of Economic Law and/or Article 101 and/or 102 TFEU.

This inspection is a preliminary step in the investigation of restrictive practices. Conducting inspections does not prejudice the outcome of the investigation itself. The BCA respects the rights of defence, in particular the right of companies to be heard in the course of the proceedings. The duration of the investigation will depend on several factors, including the degree of complexity of the case, the cooperation of the undertakings concerned with the BCA and the exercise of the rights of defence.

**For more information you may contact:**

Véronique Thirion

Prosecutor-general

Tel: +32 (2) 277 93 53

E-mail: [veronique.thirion@bma-abc.be](mailto:veronique.thirion@bma-abc.be)Website: [www. www. belgiancompetition.be](http://www.belgiancompetition.be)

The Belgian Competition Authority (BCA) is an independent administrative authority that contributes to the definition and implementation of competition policy in Belgium. Concretely, the BCA pursues anti-competitive practices, such as cartels and abuses of a dominant position, and reviews the main merger operations. The BCA cooperates with the other competition authorities of the member states of the European Union and the European Commission within the European Competition Network (ECN)